Summary: Evaluated rosuvastatin 40 mg daily versus atorvastatin 80 mg daily in patients with coronary disease, not previously on statin therapy and an LDL level > 100 mg/dL. The primary endpoint of a decrease percent atheroma volume was equal in the two groups. Rosuvastatin reduced LDL levels and raised HDL levels more than atorvastatin. There was increased liver function abnormalities with atorvastatin, higher risk of proteinuria with rosuvastatin and no difference in diabetes control.

Original Publication:

N Engl J Med. 2011 Dec 1;365(22):2078-87

Eponym: Study of Coronary Atheroma by Travascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN Trial